High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
作者： S Lockhart , W Plunkett , S Jeha , I Ramirez , T Zipf
DOI: 10.1200/JCO.1994.12.3.587
关键词:
摘要: PURPOSEThis phase I/II study was designed to explore the feasibility, toxicity, and potential efficacy of administering high-dose continuous intravenous mercaptopurine (6MP) followed by intermediate-dose cytarabine (Ara-C) children with relapsed or unresponsive acute leukemia.PATIENTS AND METHODSTwenty-three leukemia (13 myeloid, 10 lymphoid) were entered onto study. After initial hydration alkalinization, 1,000 1,250 mg/m2 6MP administered infusion over 24 hours. Following another period hydration, 500 Ara-C daily for 4 days. In 17 children, plasma concentrations measured at hours 4, 24, 27 infusions. Plasma 8, 48, 72, 96 Intracellular triphosphate (Ara-CTP) in peripheral-blood cel...
sci-hub.se 参考文章(25)
J. Mirro, W. R. Crom, D. K. Kalwinsky, V. M. Santana, D. K. Baker, J. Belt, Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Haematology and blood transfusion. ,vol. 32, pp. 82- 87 ,(1989) , 10.1007/978-3-642-74621-5_13
David G. Poplack, Lawrence J. Ettinger, Solomon Zimm, Jean Belasco, Barton A. Kamen, Jerry M. Collins, Lawrence E. Lavi, Teresa J. Vietti, Nancy Cogliano-Shutta, John S. Holcenberg, Frank Balis, Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Research. ,vol. 45, pp. 1869- 1873 ,(1985)
Gordon D. Mengel, Linda Bostwick, Elizabeth A. Musser, John S. Evans, The Effect of 1-β-d-Arabinofuranosylcytosine Hydrochloride on Murine Neoplasms Cancer Research. ,vol. 24, pp. 1285- 1293 ,(1964)
G. A. LePage, Takeo Kaneko, Effective means of reducing toxicity without concomitant sacrifice of efficacy of carcinostatic therapy. Cancer Research. ,vol. 29, pp. 2314- 2318 ,(1969)
David G. Poplack, Prem K. Narang, Andrea J. Gillespie, Peter C. Adamson, John S. Holcenberg, Robert F. Murphy, Carola A. Arndt, Frank M. Balis, Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study. Cancer Research. ,vol. 51, pp. 6079- 6083 ,(1991)
R B Weiss, W J Baker, G L Royer, Cytarabine and neurologic toxicity. Journal of Clinical Oncology. ,vol. 9, pp. 679- 693 ,(1991) , 10.1200/JCO.1991.9.4.679
M. Snook, G. P. Jamieson, J. S. Wiley, L. R. Finch, Degradation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate in Human Leukemic Myeloblasts and Lymphoblasts Cancer Research. ,vol. 47, pp. 3130- 3135 ,(1987)
N Hakami, A T Look, P C Steuber, J Krischer, R Castleberry, R Harris, Y Ravindranath, T J Vietti, Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study. Journal of Clinical Oncology. ,vol. 5, pp. 1022- 1025 ,(1987) , 10.1200/JCO.1987.5.7.1022
V Heinemann, E Estey, M J Keating, W Plunkett, Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. Journal of Clinical Oncology. ,vol. 7, pp. 622- 628 ,(1989) , 10.1200/JCO.1989.7.5.622
Timothy S. Gee, Kou-Ping Yu, Bayard D. Clarkson, Treatment of adult acute leukemia with arabinosylcytosine and thioguanine Cancer. ,vol. 23, pp. 1019- 1032 ,(1969) , 10.1002/1097-0142(196905)23:5<1019::AID-CNCR2820230506>3.0.CO;2-N